These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28643624)

  • 1. Preclinical Efficacy Testing of New Drug Candidates.
    Nuermberger EL
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28643624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using animal models to develop new treatments for tuberculosis.
    Nuermberger E
    Semin Respir Crit Care Med; 2008 Oct; 29(5):542-51. PubMed ID: 18810687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical testing of new drugs for tuberculosis: current challenges.
    Lenaerts AJ; Degroote MA; Orme IM
    Trends Microbiol; 2008 Feb; 16(2):48-54. PubMed ID: 18182291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.
    Franzblau SG; DeGroote MA; Cho SH; Andries K; Nuermberger E; Orme IM; Mdluli K; Angulo-Barturen I; Dick T; Dartois V; Lenaerts AJ
    Tuberculosis (Edinb); 2012 Nov; 92(6):453-88. PubMed ID: 22940006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
    Cavaleri M; Manolis E
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.
    Nuermberger E; Sizemore C; Romero K; Hanna D
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1177-82. PubMed ID: 26824941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
    van den Boogaard J; Kibiki GS; Kisanga ER; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2009 Mar; 53(3):849-62. PubMed ID: 19075046
    [No Abstract]   [Full Text] [Related]  

  • 8. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of new antituberculosis drugs in mouse models.
    Davies GR; Pym AS; Mitchison DA; Nuermberger EL; Grosset JH
    Antimicrob Agents Chemother; 2007 Jan; 51(1):403; author reply 403-4. PubMed ID: 17182861
    [No Abstract]   [Full Text] [Related]  

  • 10. Dormancy models for Mycobacterium tuberculosis: A minireview.
    Alnimr AM
    Braz J Microbiol; 2015; 46(3):641-7. PubMed ID: 26413043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
    de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase.
    Palencia A; Li X; Bu W; Choi W; Ding CZ; Easom EE; Feng L; Hernandez V; Houston P; Liu L; Meewan M; Mohan M; Rock FL; Sexton H; Zhang S; Zhou Y; Wan B; Wang Y; Franzblau SG; Woolhiser L; Gruppo V; Lenaerts AJ; O'Malley T; Parish T; Cooper CB; Waters MG; Ma Z; Ioerger TR; Sacchettini JC; Rullas J; Angulo-Barturen I; Pérez-Herrán E; Mendoza A; Barros D; Cusack S; Plattner JJ; Alley MR
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6271-80. PubMed ID: 27503647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Tanner L; Evans JC; Seldon R; Jordaan A; Warner DF; Haynes RK; Parkinson CJ; Wiesner L
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427302
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical study of new TB drugs and drug combinations in mouse models.
    Nikonenko BV; Sacksteder KA; Hundert S; Einck L; Nacy CA
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):102-16. PubMed ID: 18673123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
    Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for new antitubercular drugs.
    Duncan K; Barry CE
    Curr Opin Microbiol; 2004 Oct; 7(5):460-5. PubMed ID: 15451500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models in tuberculosis research - where is the beef?
    Myllymäki H; Niskanen M; Oksanen KE; Rämet M
    Expert Opin Drug Discov; 2015; 10(8):871-83. PubMed ID: 26073097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S267-S273. PubMed ID: 30496455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.